Bronson Crouch

Mr. Crouch is an entrepreneur and investor with over 15 years of experience in the biotechnology and pharmaceutical industry. Mr. Crouch is currently the Managing Partner of Curative Ventures, a private equity investment firm focused on biopharma opportunities. Key investments in the recent past include CoStim Pharmaceuticals, Inc., an immuno-oncology-focused biotech company (acquired by Novartis in 2014), TCR2 Therapeutics, Inc. (Nasdaq: TCRR), a cell therapy company, Peloton Therapeutics, Inc., an oncology biotech company focused on renal cell cancer (acquired by Merck in 2019 for $1.1 Billion cash upfront) and iTeos Therapeutics, Inc., (Nasdaq: ITOS) an immuno-oncology biotechnology company.